Brasso C, et al. - In this review, the researchers aimed to summarize available data relating to efficacy, safety, tolerability and costs of paliperidone palmitate 3-month (PP3M), and to describe hospitalization rate, occupational status, treatment preference, satisfaction, adherence and caregiver burden of patients with schizophrenia who participate in PP3M clinical trials. Furthermore, they investigated ethical implications, pros and cons of PP3M use and proposed study designs to further evaluate PP3M. The only 3-monthly long-acting injectable antipsychotic available in the market was PP3M. This made it a unique option for treatment, which could be chosen both in early and advanced phases of illness.